BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 02/07/2025

FDA Draft Guidance for Myelodysplastic Syndromes Treatment

The FDA is releasing a draft guidance to help industry sponsors develop drug and biological products for treating myelodysplastic syndromes (MDS), focusing on disease-modifying treatments and excluding supportive products like erythropoiesis-stimulating agents.

Source: Federal Register — Food and Drug AdministrationOpen original release →